Company / Current Assets per Share
Enliven Therapeutics, Inc. Current Assets per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets per Share
$6.76
FY2024
5-year range
$4.28 / $24.89
FY2020-FY2024
Trend
-9.7%
vs FY2023
Sector context
#109 of 210
Health Care
What the data says
At $6.76, Enliven Therapeutics, Inc.'s current assets per share ranks #109 of 210 in the Health Care sector. Declined from $24.89 to $6.76 over the past 2 years.
Based on SEC 10-K filings.
6.76 in FY2024 with a 5-year CAGR of -31.1%.
Declined from $24.89 to $6.76 over the past 2 years.
Health Care sector context is included.
Current Assets per Share over time
Growth rates
- 3-Year CAGR
- +16.5%
- 5-Year CAGR
- -31.1%
- 10-Year CAGR
- -
Sector benchmark
#109 of 210 in Health CareTop 52% of 210This company $6.76 Sector average $134.38
▼
-95.0% below sector average
Key checks
Key Insights
- In FY2024, current assets per share decreased 9.7% year-over-year.
- Ranks #109 out of 210 companies in the Health Care sector.
- Peak current assets per share was recorded in FY2019.
- Lowest current assets per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Assets per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $6.76 | -9.7% |
| FY2023 | $7.49 | -69.9% |
| FY2022 | $24.89 | +481.6% |
| FY2021 | $4.28 | -34.1% |
| FY2020 | $6.49 | -85.1% |
| FY2019 | $43.60 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026